Auralena

Linaglipt

·         Seguridad CVS demostrada en pacientes con DM2 y alto riesgo cardiorrenal1

·         Eficacia glucémica demostrada durante 52 semanas en pacientes con insuficiencia renal grave2

·         Bajo riesgo de hipoglicemia3

 Referencias

1. Rosenstock J, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019 Jan 1;321(1):69-79.

2.McGill JB, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013 Feb;36(2):237-44.

3. Nauck M, et al. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. Int J Clin Pract. 2018 Oct;72(10):e13240.